TMCnet - World's Largest Communications and Technology Community

TMCNet:  Vaxenta Inc. Announces Filing of International Patent for Novel Cancer Vaccine

[January 01, 2014]

Vaxenta Inc. Announces Filing of International Patent for Novel Cancer Vaccine

SAN DIEGO --(Business Wire)--

Vaxenta Biotechnologies announces the filing of a Patent Cooperation Treaty (PCT) application (SN: PCT/US13/55632) to the World Intellectual Property Organization (WIPO) covering a biological immunotherapeutic platform against cancer. The international patent has been filed on August 19th, 2013 with a priority date of August 20th, 2012 based on the provisional filing. This patent application enables Vaxenta to pursue further stages of development which, once commercialized, have the potential to provide a novel treatment to allow for sustainable recovery of cancer patients.

Years of research in the cancer field has culminated in Vaxenta's discovery and development of an innovative immunotherapeutic vaccine: XenUvaX. This revolutionary cancer treatment can benefit patients due to its unique strategy focused on re-awakening the immune system. Although still in pre-clinical trials, XenUvaX has been proven effective in training the immune system of rodent species to recognize and target foreign markers, called antigens, presented on cancer cells. Additionally, XenUvaX stimulates the immune system to detect cancer mutations, evasion mechanisms, and growth factors eliminating outlets for the cancer to evade the vaccine's effect.

Murine studies have dmonstrated efficacy in both colon and melanoma cancer models. Vaxenta plans to target melanoma as the initial indication for XenUvaX; however, the research will be expanded to include prostate, ovarian, bladder, lung and breast cancer. Vaxenta aims to develop a comprehensive solution through which the body is equipped with adequate resources to combat multiple forms of cancer.

The founder and CEO of Vaxenta Biotechnologies, Boris Markosian, stated, "Our Company will excel in the development of an immunotherapeutic agent effective against various cancer indications and is anticipating more positive results from ongoing experiments."

The PCT application will allow the company to enforce its intellectual property rights in over 140 countries as well as help to facilitate its international expansion within the near future. Vaxenta's goal is to develop its unique immunotherapeutic vaccine to safely recognize, fight and prevent cancer with a treatment that will be readily accessible worldwide in the near future. With safety in mind, Vaxenta plans to continue to innovate in the space of immunotherapy and provide a natural alternative to current chemical treatments.

[ Back To Technology News's Homepage ]


Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2014 Technology Marketing Corporation. All rights reserved.